Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM).

J. Freise (Hannover, Germany), M. Klingenberg (Hannover, Germany), J. Fuge (Hannover, Germany), T. Welte (Hannover, Germany)

Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Freise (Hannover, Germany), M. Klingenberg (Hannover, Germany), J. Fuge (Hannover, Germany), T. Welte (Hannover, Germany). Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM).. 3685

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis.
Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Year: 2018



Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma
Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Year: 2008


Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt-1, VEGF-R2-KDR/Flk-1) as prognostic indicators in small cell lung carcinomas (SCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


A role for vascular endothelial growth factor (VEGF) in fibrosis?
Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung
Year: 2009

Vascular endothelial growth factor (VEGF) and airway inflammation in COPD. Correlation with pulmonary function
Source: Eur Respir J 2006; 28: Suppl. 50, 653s
Year: 2006

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in NSCLC
Source: Eur Respir J 2005; 26: Suppl. 49, 459s
Year: 2005

Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Vascular endothelial growth factor (VEGF) , a specific marker of angiogenesis, is increased in asthmatic airways following allergen challenge
Source: Eur Respir J 2004; 24: Suppl. 48, 227s
Year: 2004

Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung
Source: Eur Respir J 2006; 28: Suppl. 50, 822s
Year: 2006

Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105)
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009

Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008


Increased vascular endothelial growth factor (VEGF) secretion from activated T cells in COPD
Source: Annual Congress 2007 - Cell-based tissue modulation: the good and the ugly?
Year: 2007


Vascular endothelial growth factor (VEGF) and bronchial wall remodelling in asthma
Source: Annual Congress 2004 - Genetics and molecular mechanisms of COPD and asthma
Year: 2004


Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 350s
Year: 2005

Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients
Source: Eur Respir J 2003; 22: Suppl. 45, 173s
Year: 2003

Vascular endothelial growth factor (VEGF) mRNA isoforms in an animal model of acute lung injury
Source: Annual Congress 2003 - Animal models of lung injury: useful or not?
Year: 2003


Vascular endothelial growth factor (VEGF) and CD31 expression in experimental prosthetic tracheal replacement
Source: Annual Congress 2009 - Current challenges in thoracic surgery
Year: 2009



The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF)
Source: Eur Respir J 2004; 24: Suppl. 48, 553s
Year: 2004

Vascular endothelial growth factor (VEGF) levels in induced sputum and plasma in asymptomatic and COPD smokers. Correlation with airway and systemic inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 652s
Year: 2006

A comparative study of two angiogenic factors: vascular endothelial growth factor (VEGF) and angiogenin (Ang) in induced sputum from asthmatic children in acute attack
Source: Eur Respir J 2006; 28: Suppl. 50, 258s
Year: 2006